PDS Biotechnology Corporation (PDSB)
Market Cap | 263.85M |
Revenue (ttm) | n/a |
Net Income (ttm) | -42.04M |
Shares Out | 30.82M |
EPS (ttm) | -1.45 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 4,172,480 |
Open | 8.60 |
Previous Close | 6.72 |
Day's Range | 7.32 - 8.92 |
52-Week Range | 2.89 - 13.65 |
Beta | 1.87 |
Analysts | Strong Buy |
Price Target | 18.25 (+113.2%) |
Earnings Date | May 15, 2023 |
About PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PDSB stock is "Strong Buy." The 12-month stock price forecast is $18.25, which is an increase of 113.20% from the latest price.
News

PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
Interim data being presented at ASCO 2023 Annual Meeting Demonstrated median progression-free survival (PFS) of 10.4 months Demonstrated 12-month overall survival (OS) rate of 87.1% A disease control ...

PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023 Company plans to initiate VERSATILE-003 Phase 3 clinical trial in late 2023

PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results
Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today, May 15, 2023, at 8:00 AM ET FLORHAM PARK, N.J., May 15, 2023 (GLOBE NEWSWI...

PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for ...

PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
FLORHAM PARK, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023
PDS Biotech prepares to advance PDS0101 into a Phase 3 registrational clinical trial – VERSATILE-003 – in HPV16-positive recurrent and/or metastatic head and neck cancer in 2023 PDS Biotech prepares t...

PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic HPV16-positive head and neck cancer Company has completed Phase 3 manufa...

PDS Biotech to Participate in Cantor's Future of Oncology Virtual Symposium
FLORHAM PARK, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results
FLORHAM PARK, N.J., March 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies fo...

PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
Received guidance on registrational path for combination in recurrent/metastatic, immune checkpoint inhibitor refractory head and neck cancer Received guidance on registrational path for combination i...

PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
Infectimune™ (R-DOTAP) nanoparticles significantly enhance cytokine-inducing, CD4 T cell responses compared to leading commercial adjuvants being used in approved vaccines Infectimune™ (R-DOTAP) nanop...

PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
Infectimune™ induced neutralizing antibody and robust T cell responses completely protecting animals against sickness after lethal challenge with live SARS-CoV-2 or influenza viruses Infectimune™ indu...

PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress
Abstract, titled “HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination PDS0101 immunotherapy,” highlights data generated from VERSATILE-002 Phase 2 study Ab...

PDS Biotech Announces Participation in the Channelchek Takeaway Series
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for...

PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for...

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform

PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months
Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients in National Cancer Institute-led Phase 2 clinical trial of PDS0101 triple combination Median OS of 21 ...

PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
VERSATILE-002 Phase 2 study investigating PDS0101 in combination with Merck's KEYTRUDA® (pembrolizumab) in both checkpoint inhibitor refractory and checkpoint inhibitor naïve patients VERSATILE-002 Ph...

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Frank Bedu-Addo, CEO PDS Biotechnology Corporation
NEW YORK, NY / ACCESSWIRE / December 5, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issu...

PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress
Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune® platform

PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update
FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for...

PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results
FLORHAM PARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for...

PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers
66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up of 16 months 66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up...